For people with 4-14 MHDs per month,
Emgality delivered significantly more migraine-free days vs placebo1
Emgality prevented up to 4.7 mean MHDs per month vs up to 2.8 mean MHDs with placebo, on average (p<0.001)1
ap<0.001 vs placebo.
Change from baseline in mean monthly MHDs1,9b
bLeast-square means and 95% confidence intervals are presented.
cEarliest post-baseline, prespecified assessment.
EVOLVE-1: -3.7 mean MHDs with Emgality in the first month, on average vs -1.7 mean MHDs with placebo
EVOLVE-2: -3.9 mean MHDs with Emgality in the fi rst month, on average vs -1.2 mean MHDs with placebo
Emgality significantly reduced the mean number of monthly MHDs that acute medication was used over Months 1 to 6 (p<0.001)1,10,11
- EVOLVE-1: -4.0 MHDs per month with Emgality vs -2.2 MHDs per month with placebo
- EVOLVE-2: -3.7 MHDs per month with Emgality vs -1.9 MHDs per month with placebo
SELECT IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.